TARA
Protara Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$4.07-0.73%
Price as of Jul 20, 2026
TARA financials
Protara Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $362.0K | $0.00 | $341.0K | $0.00 |
| Gross profit | -$362.0K | $0.00 | -$341.0K | $0.00 |
| Operating expenses | $64.2M | $49.2M | $43.3M | $67.1M |
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$67.1M |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M |
| EBITDA | -$57.1M | -$44.3M | -$40.1M | -$64.6M |
| Basic EPS | $-1.34 | $-2.17 | $-3.57 | $-5.86 |
| Diluted EPS | $-1.34 | $-2.17 | $-3.57 | $-5.86 |
| Balance sheet | ||||
| Cash & equivalents | $49.7M | $162.8M | $39.6M | $24.1M |
| Total assets | $209.5M | $181.5M | $79.0M | $113.3M |
| Total liabilities | $13.1M | $14.3M | $10.6M | $11.2M |
| Stockholders’ equity | $196.4M | $167.1M | $68.3M | $102.1M |
| Total debt | $3.4M | $4.5M | $5.5M | $6.4M |
| Net debt | -$46.3M | -$158.3M | -$34.1M | -$17.7M |
| Cash flow | ||||
| Operating cash flow | -$56.4M | -$35.8M | -$37.6M | -$26.5M |
| Capital expenditure | -$94.0K | -$63.0K | -$45.0K | -$120.0K |
| Free cash flow | -$56.5M | -$35.9M | -$37.6M | -$26.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | -$91.0K | -$90.0K |